A1: Manfred Marschall
CDK7 kinase pathways as a drug targeting strategy for broad antiherpesviral intervention
A2: Andrea Thoma-Kreß
Enhancing immunogenicity of Human T-cell leukaemia virus Type 1 (HTLV-1) by interfering with viral transcription
A3: Thomas Gramberg
Enhancing antiviral immunity by blocking SAMHD1 acticity
A4: Ulrich Schubert & Vladimir Temchura
Antiretroviral therapy with amendment of HIV-1-specific T-cell response
B1: Ilka Knippertz
Transcriptional targeting of dendritic cells as a new therapeutic vaccine against HIV-1
B2: Diana Dudziak & Christian H.K. Lehmann
LCMV as model for immune intervention by antigen targeting in chronic viral infections
B3: Thomas Harrer & Christiane Krystelle Nganou-Makamdop
Induction of Nef-resistant HIV-1-specific CTL responses as a new strategy for the development of HIV-1-specific therapeutic vaccines
B5: Matthias Tenbusch
Induction of tissue-resident memory T cells by gene-based vaccines as first line of defence against pathogens entering the host via mucosal surfaces
B6: Armin Ensser
An animal model of HLA-independent, chimeric antigen receptor-mediated adoptive immunotherapy against cytomegaloviruses
B7: Anita Kremer & Michael Wiesener
CMV-specific T cells for prevention and therapy of CMV reactivation in patients after kidney transplantation
B8: Kilian Schober
Ex vivo metabolic profiling of human antigen-specific T cell responses after yellow fever and SARS-CoV-2 mRNA vaccination
C1: Jutta Eichler
Towards novel HIV immunotherapeutics: bispecific antibody paratope mimics
C2: Heinrich Sticht
Structure-based design and optimisation of ligands for novel antiviral strategies
C3: Thomas Winkler & Marco Thomas
Protection from cytomegalovirus infection by antibodies
C4: Frank Neipel & Hans-Martin-Jäck
Recombinant MHV-68 as a model system for Kaposi's sarcoma-associated herpesvirus vaccine development
C5: Klaus Überla & Anja Lux
Inducing long-lasting HIV Env-specific antibody responses by intrastructural help
C6: Bettina Hohberger
Functionally active autoantibodies targeting G-protein-coupled receptors in patients with Long-COVID
